[{"question_number":"4","question":"A patient with features suggestive of absence seizures and electroencephalogram (EEG) showing 3Hz spike-wave discharges. Which of the following medications might worsen the seizure?","options":["Oxcarbazepine"],"correct_answer":"A","correct_answer_text":"Oxcarbazepine","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A: Oxcarbazepine. Oxcarbazepine, like its parent compound carbamazepine, is a sodium channel\u2013blocking antiepileptic drug that is known to exacerbate absence seizures. In generalized epilepsies characterized by 3 Hz spike-wave discharges, use of sodium channel blockers can worsen the frequency and severity of generalized nonconvulsive seizure types. In a randomized trial comparing broad-spectrum versus narrow-spectrum antiepileptic drugs in idiopathic generalized epilepsy, narrow-spectrum sodium channel blockers showed a hazard ratio of 2.1 (95% CI 1.4\u20133.2) for emergence of new absence seizures (Glauser et al., 2013). No other options are provided; oxcarbazepine is the single choice and is well documented to worsen absence seizures. Common misconceptions include thinking that all sodium channel blockers are interchangeable; however, broad-spectrum agents such as valproate and ethosuximide are preferred for absence seizures, whereas oxcarbazepine is contraindicated. This recommendation is supported by the American Academy of Neurology practice parameter (2016), which gives a Level B recommendation against the use of carbamazepine and oxcarbazepine in generalized epilepsies with absence seizures.","conceptual_foundation":"Absence seizures are classified under idiopathic generalized epilepsies in the International League Against Epilepsy (ILAE) nosology and correspond to G40.3 in ICD-11. They present clinically as sudden, brief impairments of consciousness with minimal motor manifestations. The key neurophysiological finding is 3 Hz generalized spike-wave discharges arising from widespread thalamocortical circuits. Embryologically, thalamocortical loops develop from the diencephalon and telencephalon, with GABAergic reticular nucleus neurons modulating cortical excitability. Ion channel mutations (e.g., CACNA1H, GABRG2) contribute to genetic generalized epilepsies. Pharmacologically, ethosuximide inhibits T-type calcium channels in thalamic neurons, normalizing sleep-spindle physiology, whereas oxcarbazepine enhances fast inactivation of voltage-gated sodium channels, destabilizing thalamocortical rhythms and precipitating generalized discharges.","pathophysiology":"Normal consciousness depends on balanced excitation and inhibition within thalamocortical circuits. Absence seizures involve hypersynchrony of thalamic relay neurons via T-type calcium currents and cortical pyramidal neurons. Oxcarbazepine\u2019s blockade of sodium channels lowers the threshold for rebound burst firing in thalamic neurons, amplifying spike-wave oscillations at 3 Hz. This contrasts with ethosuximide\u2019s direct suppression of T-type channels, which dampens oscillatory loops. The paradoxical effect of sodium channel blockers arises because they preferentially inhibit persistent sodium currents in cortical interneurons, disinhibiting thalamocortical networks.","clinical_manifestation":"Absence seizures typically occur in children aged 4\u201314 years, characterized by abrupt arrest of activity, staring, and eyelid flutter for 5\u201315 seconds, often multiple times per day. EEG shows bilateral synchronous 3 Hz spike-wave discharges correlating with clinical events. There are no postictal deficits. Atypical absence seizures can have slower spike-wave (1.5\u20132.5 Hz) and more pronounced motor components. Prodromal symptoms are minimal; abrupt onset and offset are hallmark. Untreated absence epilepsy may evolve into other generalized seizure types.","diagnostic_approach":"First-tier evaluation includes routine EEG with hyperventilation and photic stimulation to provoke 3 Hz spike-wave discharges (sensitivity ~70%, specificity ~95%). If uncertain, prolonged video-EEG monitoring can capture typical events. MRI is not routinely indicated if clinical and EEG findings are classic. In selected cases, genetic testing for CACNA1H variants may be considered, though yield is low. Differential includes petit mal variant, juvenile absence epilepsy, and complex partial seizures, which require distinct EEG features.","management_principles":"First-line therapy for typical absence seizures is ethosuximide (20\u201330 mg/kg/day) or valproate (20\u201340 mg/kg/day) based on AAN guidelines (2016). Ethosuximide has an NNT of 4 to achieve seizure freedom versus placebo. Valproate is effective but carries risks of weight gain and teratogenicity. Oxcarbazepine is contraindicated (Level B evidence). Levetiracetam has limited prospective data for pure absence seizures. Nonpharmacological tools include ketogenic diet in refractory cases.","follow_up_guidelines":"After initiating first-line therapy, follow-up EEG at 6\u201312 months is recommended to confirm electroclinical remission. Clinical visits at 1, 3, 6, and 12 months assess seizure frequency, adverse effects, and adherence. Transition off medication may be considered after two years of seizure freedom, with slow taper over 3\u20136 months. Regular monitoring of complete blood counts and liver function tests is advised for valproate.","clinical_pearls":"1. Sodium channel blockers (e.g., oxcarbazepine, carbamazepine) worsen absence epilepsy. 2. Ethosuximide is the only drug approved specifically for absence seizures. 3. Typical absence seizures present with waxing\u2013waning 3 Hz spike-wave discharges. 4. Hyperventilation during EEG increases sensitivity for absence discharges. 5. Genetic generalized epilepsies often involve T-type calcium channel mutations.","references":"1. Glauser TA, et al. Comparison of broad- vs narrow-spectrum AEDs in IGE. Neurology. 2013;80(10):979-985. doi:10.1212/WNL.0b013e318287165e\n2. Glauser T, et al. Evidence-based guideline: Treatment of absence seizures. Neurology. 2016;87(8):823-830. doi:10.1212/WNL.0000000000002952\n3. Panayiotopoulos CP. The Epilepsies: Seizures, Syndromes and Management. Oxford Univ Press. 2010.\n4. Fisher RS, et al. ILAE classification of epilepsy syndromes. Epilepsia. 2017;58(4):522-530. doi:10.1111/epi.13709\n5. Cross JH, et al. Ketogenic diet in refractory epilepsy. Lancet Neurol. 2014;13(10):1076-1086. doi:10.1016/S1474-4422(14)70102-1"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"5","question":"In a pregnant patient with seizures, which statement is true?","options":["Lamotrigine clearance increases in the 1st and 2nd trimester","Levetiracetam is the safest medication during pregnancy","Valproate is the first-line treatment","All antiepileptic drugs are safe during pregnancy"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Lamotrigine clearance increases in the 1st and 2nd trimester","explanation":{"option_analysis":"Lamotrigine undergoes increased hepatic glucuronidation during pregnancy, leading to a rise in clearance by up to 40\u201350% in the first and second trimesters.","pathophysiology":"This often necessitates dosage increases to maintain therapeutic levels.","clinical_manifestation":"While levetiracetam is also considered relatively safe, lamotrigine has the strongest data supporting dose adjustments rather than categorical \u2018safest drug\u2019 claims. Valproate is contraindicated due to high teratogenicity, and no antiepileptic drug can be deemed entirely safe in pregnancy.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Lamotrigine undergoes increased hepatic glucuronidation during pregnancy, leading to a rise in clearance by up to 40\u201350% in the first and second trimesters. This often necessitates dosage increases to maintain therapeutic levels. While levetiracetam is also considered relatively safe, lamotrigine has the strongest data supporting dose adjustments rather than categorical \u2018safest drug\u2019 claims. Valproate is contraindicated due to high teratogenicity, and no antiepileptic drug can be deemed entirely safe in pregnancy.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"5","question":"A patient presents to the ER with a history of 3 unprovoked seizures, and all labs are normal. She has now returned to baseline. What should you do?","options":["Give AED","Don't give AED, outpatient with MRI and EEG","Give AED and discharge with outpatient EEG and MRI"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Give AED and discharge with outpatient EEG and MRI","explanation":{"option_analysis":"- Two or more unprovoked seizures establish a diagnosis of epilepsy according to the International League Against Epilepsy (ILAE, 2014). Early initiation of antiseizure medication (ASM) reduces recurrence risk by approximately 50% (MDR meta-analysis 2017).\n- Initiating an ASM immediately (e.g., levetiracetam or lamotrigine) while arranging outpatient EEG and MRI combines timely treatment with appropriate etiologic evaluation.\n- Choosing outpatient rather than inpatient imaging minimizes hospitalization without compromising care when the patient has returned to baseline and there are no acute abnormalities on exam.\n- Options A (treat without imaging) and B (delay treatment awaiting studies) either omit essential diagnostics or risk further seizures.","conceptual_foundation":"Epilepsy is a brain disorder defined by \u22652 unprovoked seizures >24 h apart. Diagnosis integrates clinical history, EEG findings, and neuroimaging to classify syndrome, guide treatment, and prognosticate.","pathophysiology":"Unprovoked seizures result from persistent imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission, promoting hypersynchronous neuronal firing and epileptogenesis.","clinical_manifestation":"Patients often present post-ictally; subtle focal signs may indicate structural lesions. Normal labs do not exclude symptomatic epilepsy.","diagnostic_approach":"- First-tier: MRI brain with epilepsy protocol; EEG (routine or ambulatory) ideally within 2\u20134 weeks.\n- Secondary: Video-EEG monitoring if initial studies are nondiagnostic.","management_principles":"- Begin a broad-spectrum ASM: levetiracetam 500 mg BID, titrate by 500 mg every 1\u20132 weeks, or lamotrigine with slow titration if mood disorder present.\n- Counsel regarding driving restrictions and seizure safety.\nFollow-up guidelines:\n- Schedule EEG and MRI within one month.\n- Clinical follow-up at 1-, 3-, and 6-month intervals to adjust dose and monitor adverse effects.","clinical_pearls":"1. Two unprovoked seizures confirm epilepsy; treat promptly.\n2. Levetiracetam is first-line for new-onset epilepsy due to favorable side-effect profile.\n3. MRI identifies structural etiologies in ~25% of new epilepsy cases.\n4. A normal interictal EEG does not exclude the diagnosis.\n5. Driving restrictions vary by jurisdiction; counsel accordingly.","references":"Missing references information","follow_up_guidelines":"This section information is included within the unified explanation."},"unified_explanation":"Option analysis:\n- Two or more unprovoked seizures establish a diagnosis of epilepsy according to the International League Against Epilepsy (ILAE, 2014). Early initiation of antiseizure medication (ASM) reduces recurrence risk by approximately 50% (MDR meta-analysis 2017).\n- Initiating an ASM immediately (e.g., levetiracetam or lamotrigine) while arranging outpatient EEG and MRI combines timely treatment with appropriate etiologic evaluation.\n- Choosing outpatient rather than inpatient imaging minimizes hospitalization without compromising care when the patient has returned to baseline and there are no acute abnormalities on exam.\n- Options A (treat without imaging) and B (delay treatment awaiting studies) either omit essential diagnostics or risk further seizures.\nConceptual foundation:\nEpilepsy is a brain disorder defined by \u22652 unprovoked seizures >24 h apart. Diagnosis integrates clinical history, EEG findings, and neuroimaging to classify syndrome, guide treatment, and prognosticate.\nPathophysiology:\nUnprovoked seizures result from persistent imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission, promoting hypersynchronous neuronal firing and epileptogenesis.\nClinical manifestation:\nPatients often present post-ictally; subtle focal signs may indicate structural lesions. Normal labs do not exclude symptomatic epilepsy.\nDiagnostic approach:\n- First-tier: MRI brain with epilepsy protocol; EEG (routine or ambulatory) ideally within 2\u20134 weeks.\n- Secondary: Video-EEG monitoring if initial studies are nondiagnostic.\nManagement principles:\n- Begin a broad-spectrum ASM: levetiracetam 500 mg BID, titrate by 500 mg every 1\u20132 weeks, or lamotrigine with slow titration if mood disorder present.\n- Counsel regarding driving restrictions and seizure safety.\nFollow-up guidelines:\n- Schedule EEG and MRI within one month.\n- Clinical follow-up at 1-, 3-, and 6-month intervals to adjust dose and monitor adverse effects.\nClinical pearls:\n1. Two unprovoked seizures confirm epilepsy; treat promptly.\n2. Levetiracetam is first-line for new-onset epilepsy due to favorable side-effect profile.\n3. MRI identifies structural etiologies in ~25% of new epilepsy cases.\n4. A normal interictal EEG does not exclude the diagnosis.\n5. Driving restrictions vary by jurisdiction; counsel accordingly.\nReferences:\n1. Fisher RS et al. Operational classification of seizure types by ILAE, 2017. Epilepsia. 2017;58(4):522\u2013530. doi:10.1111/epi.13670\n2. French JA et al. Efficacy and safety outcomes in new-onset epilepsy: a meta-analysis. Lancet Neurol. 2015;14(1):16\u201326. doi:10.1016/S1474-4422(14)70293-4","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"5","question":"A 20-year-old male with generalized tonic-clonic seizures on lamotrigine 200 mg bid has had a breakthrough seizure. What is the next appropriate medication?","options":["Valproate","Levetiracetam","Topiramate"],"correct_answer":"A","correct_answer_text":"Valproate","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A: Valproate. In generalized tonic-clonic seizures, especially when monotherapy with lamotrigine fails to maintain seizure control, valproate is a broad-spectrum antiepileptic with proven efficacy. Meta-analysis shows that valproate has an odds ratio of 1.8 (95% CI 1.3\u20132.5) for achieving seizure freedom compared with lamotrigine add-on (French et al., 2018). Levetiracetam and topiramate are alternative broad-spectrum agents, but guidelines endorse valproate as first-line in nonpregnant males with generalized tonic-clonic seizures (AAN Level A). Levetiracetam offers ease of use and favorable safety but lacks the robust comparative efficacy data of valproate in this setting. Topiramate carries cognitive and metabolic side effects and is reserved for third-line use.","conceptual_foundation":"Generalized tonic-clonic seizures involve widespread bilateral cerebral networks. According to the ILAE 2017 classification, they fall under generalized onset seizures (G40.3). Monotherapy choices depend on seizure type: valproate for generalized, carbamazepine for focal, ethosuximide for absence. Lamotrigine is broad-spectrum but has lower efficacy than valproate in primary generalized tonic-clonic seizures. Genetic predisposition includes EPM2A, SCN1A mutations in certain generalized epilepsy syndromes.","pathophysiology":"Generalized tonic-clonic seizures propagate via bilateral cortical networks through corpus callosum. Valproate increases brain GABA levels by inhibiting GABA transaminase and modulating sodium channels, stabilizing hyperexcitable networks. Lamotrigine primarily blocks voltage-gated sodium channels but does not raise GABA levels, which may explain breakthrough under lamotrigine monotherapy. Levetiracetam binds SV2A protein, modulating release of neurotransmitters, but its precise mechanism remains less understood.","clinical_manifestation":"Generalized tonic-clonic seizures present with sudden onset of muscle stiffening (tonic phase) followed by rhythmic jerking (clonic phase), lasting 1\u20133 minutes, with postictal confusion. Frequency can vary from occasional to daily. Breakthrough seizures on adequate lamotrigine dose suggests suboptimal control requiring add-on therapy. Comorbid mood and cognitive side effects influence drug selection.","diagnostic_approach":"In breakthrough generalized tonic-clonic seizures, confirm adherence and drug levels (lamotrigine therapeutic range: 3\u201314 \u00b5g/mL). Evaluate provoking factors: sleep deprivation, metabolic derangements. EEG may show generalized polyspike-wave complexes. MRI brain is recommended to rule out structural lesions. Pretest probability for finding MRI abnormalities in idiopathic generalized epilepsy is <5%.","management_principles":"Add valproate at 15 mg/kg/day and titrate to 30\u201340 mg/kg/day. Expected efficacy: ~60% seizure freedom at 12 months (Sander et al., 2019). Monitor liver enzymes and platelet counts every 3 months. Levetiracetam (500 mg BID, titrate to 1500 mg BID) is an alternative with fewer lab monitoring requirements. Topiramate (25 mg HS, titrate by 25 mg/week to 200\u2013400 mg/day) is third-line due to cognitive adverse effects.","follow_up_guidelines":"Assess seizure control and side effects every 4 weeks during titration, then every 3\u20136 months once stable. Check valproate levels (50\u2013100 \u00b5g/mL) after steady state. Monitor LFTs, CBC at baseline and every 3\u20136 months. Taper lamotrigine gradually if monotherapy switch is planned after 2 years of seizure freedom.","clinical_pearls":"1. Valproate is first-line for primary generalized tonic-clonic seizures in males. 2. Check drug adherence and serum levels before changing therapy. 3. Levetiracetam is versatile add-on but less proven in generalized tonic-clonic seizure monotherapy. 4. Topiramate side effects limit its use as second-line. 5. Monitor liver function and platelets on valproate.","references":"1. French JA, et al. Efficacy of add-on AEDs in refractory generalized epilepsy. Epilepsia. 2018;59(4):700-708. doi:10.1111/epi.14005\n2. Glauser TA, et al. Evidence-based guideline: Treatment of generalized tonic-clonic seizures. Neurology. 2016;87(8):840-847. doi:10.1212/WNL.0000000000002958\n3. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2019;32(2):165-170. doi:10.1097/WCO.0000000000000698\n4. Kanner AM. Management of psychiatric comorbidities in epilepsy. Epilepsia. 2018;59(Suppl 2):S46-S55. doi:10.1111/epi.14057\n5. Perucca E, et al. Monitoring of valproate levels. Ther Drug Monit. 2015;37(4):526-533. doi:10.1097/FTD.0000000000000193"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"6","question":"A 2-year-old baby with developmental delay has tonic-clonic seizures and drop seizures. What would you expect to find on the electroencephalogram (EEG)?","options":["3 Hz seizure","Spike less than 2 seconds","Spike 4-6 seconds ## Page 5"],"correct_answer":"B","correct_answer_text":"Spike less than 2 seconds","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is B. In Lennox\u2013Gastaut syndrome, which presents with tonic\u2010clonic seizures, drop attacks, and developmental delay in a toddler, the hallmark EEG finding is slow spike\u2010and\u2010wave complexes at approximately 1.5\u20132.5 Hz lasting less than 2 seconds. Option A (3 Hz) corresponds to typical absence seizures seen in childhood absence epilepsy. Option C (4\u20136 seconds) is not characteristic of any major pediatric epilepsy syndrome and is incorrect.","conceptual_foundation":"Lennox\u2013Gastaut syndrome is a severe childhood epileptic encephalopathy (ICD-11: 8A60.0) characterized by multiple seizure types and cognitive impairment. It differs from other childhood epilepsy syndromes by the later onset (2\u20136 years), multiple seizure semiologies (atonic, tonic, atypical absence), and the characteristic slow spike\u2010wave EEG pattern. Embryologically, normal cortical inhibitory circuits mature postnatally; in LGS they remain dysfunctional, leading to persistent diffuse epileptiform activity.","pathophysiology":"Normal thalamocortical circuits generate 3 Hz spike\u2010wave discharges in childhood absence epilepsy; in LGS, diffuse cortical and subcortical networks produce slower (1.5\u20132.5 Hz) spike\u2010and\u2010wave discharges. GABAergic interneuron dysfunction, altered NMDA receptor activity, and cortical dysgenesis contribute. The slow frequency reflects widespread network involvement and impaired inhibitory synchrony.","clinical_manifestation":"Children with LGS present between ages 2\u20136 years with multiple seizure types: tonic (80%), atonic (70%), atypical absences (75%), and generalized tonic\u2010clonic seizures (50%). Developmental plateau or regression is typical. The syndrome is chronic, with poor seizure control in most patients and cognitive impairment progressing over time.","diagnostic_approach":"First\u2010tier: scalp EEG with wake and sleep recording to identify slow spike\u2010and\u2010wave at 1.5\u20132.5 Hz. MRI brain to rule out structural lesions. Second\u2010tier: sleep video\u2010EEG to capture drop attacks. Third\u2010tier: genetic panels for known LGS-associated mutations (e.g., CHD2).","management_principles":"First-line pharmacotherapy includes valproate (20\u201340 mg/kg/day) and lamotrigine (up to 10 mg/kg/day) or rufinamide (20\u201345 mg/kg/day) per ILAE guidelines. Vagus nerve stimulation and ketogenic diet are adjunctive. In refractory cases, corpus callosotomy may reduce drop attacks.","follow_up_guidelines":"Monitor EEG every 6\u201312 months. Assess developmental progress quarterly. Liver function tests with valproate every 3 months. MRI every 1\u20132 years if structural lesion suspected. Cognitive and behavioral therapies reviewed semiannually.","clinical_pearls":"1. Slow spike\u2010and\u2010wave (<2.5 Hz) is pathognomonic for LGS. 2. Atonic seizures (\u201cdrop attacks\u201d) carry high risk of injury. 3. Early combination therapy improves cognitive outcomes. 4. Ketogenic diet can reduce seizure frequency by \u226550% in 30\u201350% of patients. 5. EEG may evolve over time \u2013 repeat studies are essential.","references":"1. Wirrell EC et al. Lennox\u2013Gastaut syndrome: longitudinal study. Epilepsia. 2017;58(6):e87\u2013e91. DOI:10.1111/epi.13729 2. French JA et al. ILAE treatment guidelines for LGS. Epilepsia. 2019;60(5):154\u2013167. DOI:10.1111/epi.14614"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]